drugset
drugset / Trial / NCT06169059

To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

NCT06169059 ↗

Phase 1 Completed 60 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and pharmacokinetic characteristics after multiple administration of JC-013 and JLP-2004

Timeline

Start
2023-10-05
Primary completion
2023-11-08
Completion
2023-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject JC-013 Unknown — —
Subject JLP-2004 Unknown — —

Indications

No indication recorded.